Genome‐wide analysis identifies 16q deletion associated with survival, molecular subtypes, mRNA expression, and germline haplotypes in breast cancer patients

Breast carcinomas are characterized by DNA copy number alterations (CNAs) with biological and clinical significance. This explorative study integrated CNA, expression, and germline genotype data of 112 early‐stage breast cancer patients. Recurrent CNAs differed substantially between tumor subtypes classified according to expression pattern. Deletion of 16q was overrepresented in Luminal A, and a predictor of good prognosis, both overall and for the nonluminal A subgroups. The deleted region most significantly associated with survival mapped to 16q22.2, harboring the genes TXNL4B and DXH38, whose expression was strongly correlated with the deletion. The area most frequently deleted resided on 16q23.1, 3.5 MB downstream of the area most significantly associated with survival, and included the tumor suppressor gene ADAMTS18 and the cell recognition gene CNTNAP4. Whole‐genome association analysis identified germline single nucleotide polymorphisms (SNPs) and their corresponding haplotypes, residing on several different chromosomes, to be associated with deletion of 16q. The genes where these SNPs reside encode proteins involved in the extracellular matrix (CHST3 and SPOCK2), in regulation of the cell cycle (JMY, PTPRN2, and Cwf19L2) and chromosome stability (KPNB1). © 2008 Wiley‐Liss, Inc.

[1]  P. Devilee,et al.  Ever since Knudson. , 2001, Trends in genetics : TIG.

[2]  I. Ellis,et al.  Chromosome 16 tumor‐suppressor genes in breast cancer , 2006, Genes, chromosomes & cancer.

[3]  M. J. van de Vijver,et al.  Different mechanisms of chromosome 16 loss of heterozygosity in well‐ versus poorly differentiated ductal breast cancer , 2004, Genes, chromosomes & cancer.

[4]  R I Richards,et al.  Genetic heterogeneity in familial acute myelogenous leukemia: evidence for a second locus at chromosome 16q21-23.2. , 1997, American journal of human genetics.

[5]  G. Coetzee,et al.  Androgen receptor‐mediated repression of novel target genes , 2007, The Prostate.

[6]  J. Ross,et al.  The HER‐2/neu Oncogene in Breast Cancer: Prognostic Factor, Predictive Factor, and Target for Therapy , 1998, The oncologist.

[7]  Robert Tibshirani,et al.  Distinct patterns of DNA copy number alteration are associated with different clinicopathological features and gene‐expression subtypes of breast cancer , 2006, Genes, chromosomes & cancer.

[8]  P. Deloukas,et al.  The portability of tagSNPs across populations: a worldwide survey. , 2006, Genome research.

[9]  Sunil R Lakhani,et al.  The molecular genetics of breast cancer: the contribution of comparative genomic hybridization. , 2005, Pathology, research and practice.

[10]  G Kvalheim,et al.  Detection of isolated tumor cells in bone marrow is an independent prognostic factor in breast cancer. , 2003, Journal of clinical oncology : official journal of the American Society of Clinical Oncology.

[11]  Russ B. Altman,et al.  Missing value estimation methods for DNA microarrays , 2001, Bioinform..

[12]  Ajay N. Jain,et al.  Genomic and transcriptional aberrations linked to breast cancer pathophysiologies. , 2006, Cancer cell.

[13]  R. Tibshirani,et al.  Significance analysis of microarrays applied to the ionizing radiation response , 2001, Proceedings of the National Academy of Sciences of the United States of America.

[14]  P. Hall,et al.  Gene expression in 16q is associated with survival and differs between Sørlie breast cancer subtypes , 2007, Genes, Chromosomes and Cancer.

[15]  D. Botstein,et al.  Cluster analysis and display of genome-wide expression patterns. , 1998, Proceedings of the National Academy of Sciences of the United States of America.

[16]  Lester L. Peters,et al.  Genome-wide association study identifies novel breast cancer susceptibility loci , 2007, Nature.

[17]  Therese Sørlie,et al.  Presence of bone marrow micrometastasis is associated with different recurrence risk within molecular subtypes of breast cancer , 2007, Molecular oncology.

[18]  M. Meyerson,et al.  Genome-Wide Analysis of Neuroblastomas using High-Density Single Nucleotide Polymorphism Arrays , 2007, PloS one.

[19]  E. Peles,et al.  Caspr3 and Caspr4, Two Novel Members of the Caspr Family Are Expressed in the Nervous System and Interact with PDZ Domains , 2002, Molecular and Cellular Neuroscience.

[20]  J. Overgaard,et al.  Allelic loss of 16q23.2-24.2 is an independent marker of good prognosis in primary breast cancer. , 1998, Cancer research.

[21]  R. Tibshirani,et al.  Gene expression patterns of breast carcinomas distinguish tumor subclasses with clinical implications , 2001, Proceedings of the National Academy of Sciences of the United States of America.

[22]  Zhong-ying Shen,et al.  Epigenetic identification of ADAMTS18 as a novel 16q23.1 tumor suppressor frequently silenced in esophageal, nasopharyngeal and multiple other carcinomas , 2007, Oncogene.

[23]  J. Nesland,et al.  Genetic alterations of the tumour suppressor gene regions 3p, 11p, 13q, 17p, and 17q in human breast carcinomas , 1992, Genes, chromosomes & cancer.

[24]  Cheng Li,et al.  Integration of global SNP-based mapping and expression arrays reveals key regions, mechanisms, and genes important in the pathogenesis of multiple myeloma. , 2006, Blood.

[25]  B. Brandt,et al.  Cytogenetic differences in breast cancer samples between German and Japanese patients , 2005, Journal of Clinical Pathology.

[26]  Y. Ishikawa,et al.  Identification of a 910‐Kb region of common allelic loss in chromosome bands 16q24.1–q24.2 in human lung cancer , 1998, Genes, chromosomes & cancer.

[27]  A. Feinberg,et al.  A third Wilms' tumor locus on chromosome 16q. , 1992, Cancer research.

[28]  K. Gunderson,et al.  A genome-wide scalable SNP genotyping assay using microarray technology , 2005, Nature Genetics.

[29]  N. Carter,et al.  A comprehensive study of chromosome 16q in invasive ductal and lobular breast carcinoma using array CGH , 2006, Oncogene.

[30]  N. Nishida,et al.  Accumulation of allelic loss on arms of chromosomes 13q, 16q and 17p in the advanced stages of human hepatocellular carcinoma , 1992, International journal of cancer.

[31]  Christian A. Rees,et al.  Microarray analysis reveals a major direct role of DNA copy number alteration in the transcriptional program of human breast tumors , 2002, Proceedings of the National Academy of Sciences of the United States of America.

[32]  S. Gabriel,et al.  The Structure of Haplotype Blocks in the Human Genome , 2002, Science.

[33]  R. Tibshirani,et al.  Repeated observation of breast tumor subtypes in independent gene expression data sets , 2003, Proceedings of the National Academy of Sciences of the United States of America.

[34]  Y. Shang,et al.  DLP, a Novel Dim1 Family Protein Implicated in Pre-mRNA Splicing and Cell Cycle Progression* , 2004, Journal of Biological Chemistry.

[35]  J. Gray,et al.  Amplification of chromosomal region 20q13 in invasive breast cancer: prognostic implications. , 1995, Clinical cancer research : an official journal of the American Association for Cancer Research.

[36]  K. Gunderson,et al.  High-resolution genomic profiling of chromosomal aberrations using Infinium whole-genome genotyping. , 2006, Genome research.

[37]  G. Berx,et al.  E-cadherin is inactivated in a majority of invasive human lobular breast cancers by truncation mutations throughout its extracellular domain. , 1996, Oncogene.

[38]  A. Hanby,et al.  Comparative genomic hybridization of breast tumors stratified by histological grade reveals new insights into the biological progression of breast cancer. , 1999, Cancer research.

[39]  Hur-Li Lee,et al.  What is a collection? , 2000, J. Am. Soc. Inf. Sci..

[40]  D. Gudbjartsson,et al.  Common variants on chromosomes 2q35 and 16q12 confer susceptibility to estrogen receptor–positive breast cancer , 2007, Nature Genetics.

[41]  Mark Daly,et al.  Haploview: analysis and visualization of LD and haplotype maps , 2005, Bioinform..

[42]  Michael Baudis,et al.  Genetic losses in breast cancer: toward an integrated molecular cytogenetic map. , 2005, Cancer genetics and cytogenetics.

[43]  Christian A. Rees,et al.  Molecular portraits of human breast tumours , 2000, Nature.

[44]  Holger Schwender,et al.  Modifying Microarray Analysis Methods for Categorical Data - SAM and PAM for SNPs , 2004, GfKl.

[45]  O. Kallioniemi,et al.  Somatic genetic alterations in BRCA2‐associated and sporadic male breast cancer , 1999, Genes, chromosomes & cancer.

[46]  May D. Wang,et al.  GoMiner: a resource for biological interpretation of genomic and proteomic data , 2003, Genome Biology.

[47]  M. Emi,et al.  Three distinct commonly deleted regions of chromosome arm 16q in human primary and metastatic prostate cancers , 1996, Genes, chromosomes & cancer.

[48]  Ingrid K. Glad,et al.  CGH-Explorer: a program for analysis of array-CGH data , 2005, Bioinform..

[49]  Wen-Lin Kuo,et al.  A collection of breast cancer cell lines for the study of functionally distinct cancer subtypes. , 2006, Cancer cell.

[50]  S. Hilsenbeck,et al.  Genetic aberrations detected by comparative genomic hybridization predict outcome in node-negative breast cancer. , 1995, The American journal of pathology.

[51]  L. Hartmann,et al.  Involvement of H-cadherin (CDH13) on 16q in the region of frequent deletion in ovarian cancer. , 1999, International journal of oncology.